Calliditas Therapeutics AB
www.calliditas.se/en/
Latest From Calliditas Therapeutics AB
Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease
Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US
Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.
Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate
While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.
Calliditas IPO To Support Phase III Berger's Disease Study
Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Therapeutic Areas
- Renal System
- Alias(es)
- Pharmalink AB
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Scandinavia
-
Sweden
-
Sweden
-
Scandinavia
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Calliditas Therapeutics AB
- Senior Management
-
Renee Aguiar-Lucander, CEO
Fredrik Johansson, CFO
Jens Kristensen, PhD, CMO - Contact Info
-
Calliditas Therapeutics AB
Phone: (46) 8 411 3005
Wallingatan 26B
Stockholm, SE-114 24
Sweden
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice